Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The blood test, known as the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio, can be used to detect amyloid plaques ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

ARUP Laboratories has introduced a blood test for phosphorylated tau 217 (pTau 217) to aid in diagnosing the pathology of Alzheimer's disease in individuals aged 60 years and above experiencing ...

SALT LAKE CITY, April 21, 2025 /PRNewswire/ -- ARUP Laboratories now provides a blood test for phosphorylated tau 217 (pTau 217) to assist in identifying whether cognitive decline symptoms in ...

The pTau 217 Blood Test is something that’s been worked on for years at ARUP Laboratories on the University of Utah’s campus. “We need to make sure that the performance characteristics of ...

(BUSINESS WIRE )--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in ...